Bayberry (Myrica rubra)

Bayberry (Myrica rubra) is a polyphenol-rich fruit containing cyanidin-3-glucoside (C3G, 68–95% of total anthocyanins), myricetin, myricitrin, and dihydromyricetin, which collectively exert potent antioxidant, anti-inflammatory, and cardioprotective effects through NF-κB pathway inhibition, free radical scavenging, and CYP enzyme modulation (Sun C et al., Plant Foods Hum Nutr, 2013; PMID 23605674). A comprehensive review confirmed that myricetin—a signature flavonol in Myrica rubra—demonstrates anticancer, antidiabetic, anti-inflammatory, and neuroprotective activities across in vitro and in vivo models, with IC₅₀ values in the low micromolar range against multiple oxidative and inflammatory targets (Song X et al., Biomed Pharmacother, 2021; PMID 33338751).

Origin & History

Bayberry (Myrica rubra) is a fruit-bearing tree native to East Asia, primarily found in China, Japan, and Korea. A distinct species from the North American Bayberry (Myrica pensylvanica), this East Asian variety is celebrated for its vibrant, sweet-tart fruit and its rich profile of bioactive compounds.

Historical & Cultural Context

In East Asian cultures, Bayberry (Myrica rubra) has been valued for centuries for its contributions to respiratory and digestive health. Historically used for fevers, colds, and gastrointestinal wellness, it symbolized vitality and resilience, with its fruit also traditionally used in culinary and ceremonial contexts.

Health Benefits

- Supports respiratory health by acting as an astringent and expectorant.
- Enhances immune resilience through its antimicrobial and antiviral actions.
- Promotes digestive wellness by soothing gastrointestinal inflammation and balancing gut microbiota.
- Combats oxidative stress, supporting cellular vitality and healthy aging.
- Supports cardiovascular health by regulating blood pressure and improving circulation.
- Aids stress management and emotional balance through its mild adaptogenic effects.

How It Works

Cyanidin-3-glucoside (C3G) scavenges DPPH, ABTS, and H₂O₂ radicals at concentrations as low as 0.25 mg/mL, while preventing p65 nuclear translocation in the NF-κB inflammatory cascade, thereby reducing secretion of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in macrophage models (PMID 23605674). Myricetin inhibits cyclooxygenase-2 (COX-2) expression, suppresses MAPK/ERK and PI3K/Akt signaling, and activates Nrf2-mediated antioxidant response element (ARE) genes including heme oxygenase-1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1) (PMID 33338751). Dihydromyricetin ameliorates hyperuricemia by inhibiting uric acid reabsorption via modulation of URAT1 and GLUT9 renal urate transporters (PMID 40202030). Myricitrin additionally downregulates iNOS-derived nitric oxide production and attenuates LPS-induced inflammatory signaling in neuronal and hepatic cell lines, suggesting broad multi-organ protective mechanisms (PMID 30474534).

Scientific Research

Sun C et al. (2013) published a comprehensive review in Plant Foods for Human Nutrition (PMID 23605674) detailing Myrica rubra's antioxidant, anticancer, anti-inflammatory, antibacterial, and antidiarrheal biological activities derived from its anthocyanins, flavonols, and ellagitannins. Song X et al. (2021) in Biomedicine & Pharmacotherapy (PMID 33338751) reviewed myricetin's pharmacology, demonstrating its anti-inflammatory efficacy via NF-κB and MAPK pathway suppression, antitumor activity in breast and colon cancer cell lines, and cardioprotective effects in animal models. Silva BJ et al. (2015) in the International Journal of Molecular Sciences (PMID 26225964) confirmed significant antioxidant and anti-inflammatory effects of Morella and Myrica species, attributing them to myricitrin, myricetin glycosides, and proanthocyanidins. Rosa GP et al. (2020) in Molecules (PMID 33371425) further characterized phytochemicals from Myrica species, identifying diarylheptanoids, cyclic myricanol, and triterpenes as additional bioactive agents with cytotoxic and antiviral potential.

Clinical Summary

Current evidence for Myrica rubra is limited to in vitro cellular studies and animal models, with no human clinical trials reported. Laboratory studies demonstrate that 'Dongkui' extract at 0.25 mg/mL significantly inhibits LPS-induced TNF-α production in RAW 264.7 macrophages compared to other cultivar extracts. Animal studies show C3G prevents antibiotic-associated diarrhea by restoring inflammatory markers to control levels through dose-dependent NF-κB inhibition. The evidence base requires human clinical validation to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

- Fiber
- Vitamin C
- Calcium, Magnesium, Potassium
- Flavonoids, Phenolic acids, Tannins, Triterpenes, Anthocyanins, Polyphenols

Preparation & Dosage

- Common forms include fresh fruit, dried fruit or bark for tea, and standardized extracts.
- Dosage: For tea, steep 1–2 teaspoons of dried fruit or bark in hot water, consumed up to twice daily; for standardized extracts, 300–600 mg per day.
- Traditionally used in East Asian medicine to support digestive health, treat fatigue, and improve immune function.

Synergy & Pairings

Role: Polyphenol/antioxidant base
Intention: Gut & Microbiome | Immune & Inflammation
Primary Pairings: - Turmeric (Curcuma longa)
- Camu Camu
- Ginger (Zingiber officinale)
- Maca Root (Lepidium meyenii)

Safety & Interactions

Bayberry fruit has been associated with allergic reactions including documented cases of anaphylaxis, with cross-sensitivity reported to peaches, cherries, and other Rosaceae fruits. In vitro studies indicate that Myrica rubra extracts inhibit CYP3A4 and CYP2C9 enzymes, suggesting potential interactions with drugs metabolized by these isoforms, including warfarin, statins, calcium channel blockers, and certain immunosuppressants. Bayberry's hypotensive flavonoids may potentiate the effects of antihypertensive medications, warranting caution in patients on ACE inhibitors or ARBs. Safety data in pregnancy and lactation are absent, and use should be avoided in these populations; no standardized dosing has been established due to insufficient clinical trial data.